Quiz: Umbralisib Plus Ublituximab for Patients With TN, PT CLL

11/22/2021

Recent News

News

Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS

09/19/2024

Amber Denham ;

An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...

An initial treatment of low...

09/19/2024

Oncology

News

Combination Therapy Followed by Brentuximab Vedotin Consolidation Demonstrated Safety, Activity Among Patients With CD30-Expressing Peripheral T-Cell Lymphomas

09/19/2024

Amber Denham ;

Cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide, with or without autologous hematopoietic stem-cell transplantation, plus brentuximab vedotin consolidation demonstrated safety and activity for patients with...

Cyclophosphamide, doxorubicin,...

09/19/2024

Oncology

News

FDA Approves First-Line Pembrolizumab Plus Chemotherapy for Patients With Unresectable Advanced Malignant Pleural Mesothelioma

09/18/2024

Stephanie Holland ;

Based on results from the KEYNOTE-483 study, the US FDA has approved pembrolizumab plus pemetrexed and platinum-based chemotherapy as first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Based on results from the...

09/18/2024

Oncology

FDA Alerts

FDA Grants Approval to Ribociclib With Aromatase Inhibitor and Letrozole Co-Pack for Adjuvant Treatment of HR-Positive HER2-Negative High-Risk Breast Cancer

09/17/2024

Gina Tomaine ;

On September 17, 2024, the FDA approved ribociclib with an aromatase inhibitor as well as a ribociclib and letrozole co-pack for the adjuvant treatment of adults with hormone receptor-positive, HER2-negative stage II and III early breast...

On September 17, 2024, the FDA...

09/17/2024

Oncology

News

Management of Adverse Events Associated With Selumetinib for Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

09/17/2024

Allison Casey ;

A panel of experts provided consensus recommendations on prevention, early detection, and management of adverse events potentially associated with selumetinib among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

A panel of experts provided...

09/17/2024

Oncology

News

New Risk Stratification Model Provides Prognostic Data on Survival Post-AlloHCT for Older Patients With AML and High-Risk MDS

09/17/2024

Amber Denham ;

The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...

The AML60+ classification system...

09/17/2024

Oncology

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology